Eli Lilly is set to acquire Kelonia Therapeutics for up to $7 billion, securing an innovative cancer therapy that reprograms immune cells within the patient's body. This move marks a significant expansion for Lilly into cell therapy, an area they have actively developed through recent acquisitions.
The agreement includes an upfront payment of $3.25 billion, with the remainder contingent on clinical and commercial success. The deal is expected to finalize in the latter half of 2026, pending regulatory approval.
Kelonia's primary candidate, KLN-1010, targets multiple myeloma. Unlike current cell therapies requiring extensive lab work and patient reinfusion, KLN-1010 aims for in vivo reprogramming via a single IV infusion, potentially reducing the cost and complexity of treatment.
Early human trial data for KLN-1010 showed no detectable cancer cells in all four treated patients, with responses sustained up to three months. The therapy also demonstrated strong CAR-T cell expansion without preconditioning chemotherapy.
The acquisition places Lilly in a competitive cell therapy market, following recent high-value deals by industry peers. Jacob Van Naarden of Eli Lilly highlighted the encouraging early clinical data for KLN-1010. Kevin Friedman, CEO of Kelonia Therapeutics, stated their platform technology is designed to extend cell therapy applications beyond current CAR-T limitations to a broader range of diseases.